Adjust text size

Dr. Sujit Nair
Professor (MPharm, PhD (USA))

He received his doctoral degree in Pharmaceutical Sciences from Rutgers, The State University of New Jersey, USA where he was affiliated for six years with the Center for Cancer Chemoprevention Research at the Ernest Mario School of Pharmacy. He received his Masters and Bachelors degrees in Pharmacy from the University of Mumbai. He has published in peer-reviewed international journals and has an h-index of 20 with over 2100 citations. In addition, he has over 175 peer reviews and editorial records on Publons.

Google Scholar Profile:

Publons Profile:

Specialization: Pharmaceutics

Experience: 19 years (Academics: 19 years)

Thrust Research areas:

Cancer Nanobiomedicine

Cancer Pharmacogenomics

Nutraceutical Clinical Trials and Pharmacokinetics

Publications/ Presentations:

Publications: 50 (International-50)

Presentations: 65

Books/Book chapters: 3

Patents:  3 in process

Research/ Sponsored projects:  

3 completed projects on regulatory cancer microRNA, siRNA knockdown and genotype analysis, DBT & ICMR, total outlay of Rs. 1.5 crores


Member, International Expert Panel, National Medical Research Council, Ministry of Health, Government of Singapore

Co-Editor-in-Chief, Current Pharmacogenomics and Personalized Medicine (Bentham, UAE)

Associate Editor, Drug Metabolism and Personalized Therapy (De Gruyter, Germany)

Section Editor: Precision Medicine and Pharmacogenomics, Current Pharmacology Reports (Springer, USA)

Editorial Board, Advances in Modern Oncology Research (Pisco Med, Singapore)

Research students guided

He has guided 52 MPharm/MSc/MTech students for their research projects.

He has guided/co-guided 2 PhDs successfully.  

Recent Publications 

  • Jain R and Nair S. Sandalwood oil for the chemoprevention of skin cancer: Mechanistic insights, anti-inflammatory and in vivo anticancer potential. Current Pharmacology Reports 2019. In press. Springer.
  • Nair S and Llerena A. Editorial: New vistas in personalized medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics. Drug Metabolism and Personalized Therapy 2018; 33(2): 61-63.
  • Nair S and Kong AN. Emerging roles for clinical pharmacometrics in cancer precision medicine. Current Pharmacology Reports 2018; 4(3):276-283.
  • Nair S, Iyer A, Vijay V, Bandlamudi S and Llerena A. Pharmacokinetics and systems pharmacology of monoclonal antibody olaratumab for inoperable soft tissue sarcoma. Advances in Modern Oncology Research 2017; 3(3): 1-12.
  • Nair S. Pharmacometrics and systems pharmacology of immune checkpoint inhibitor nivolumab in cancer translational medicine. Advances in Modern Oncology Research 2016; 2(1):18-31 (More than 2000 views and 1000 downloads; Article was second amongst top ten most Accessed articles of 2016 for this journal).
  • Nair S and Kong AN. Pharmacometrics of nutraceutical sulforaphane and its implications in prostate cancer prevention. Journal of Chinese Pharmaceutical Sciences 2016; 25(1):12-22.
  • Nair S. Current insights into the molecular systems pharmacology of lncRNA-miRNA interactions and implications in cancer translational medicine. AIMS Molecular Science 2016; 3(2):104-124.
  • Nair S, Liew C, Khor TO, Cai L, Kong AN. Elucidation of regulatory interaction networks underlying human prostate adenocarcinoma. Journal of Chinese Pharmaceutical Sciences 2015; 24(1): 12-27.
  • Nair S and Kong AN. Architecture of miRNA regulatory networks in cancer chemoprevention. Current Pharmacology Reports 2015; 1:89-101.

Professional Memberships

  • International Society for the Study of Xenobiotics (ISSX)
  • European Society of Pharmacogenomics and Personalized Therapy (ESPT)
  • American Association of Pharmaceutical Scientists (AAPS)
  • American Association of Cancer Research (AACR)
  • Indian Association for Cancer Research (IACR)
  • Registered Pharmacist, Maharashtra State Pharmacy Council


E-mail: sujit.nair

Tel. (O): 022-4233 2052 (Ext. 2110)